Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib's Effects on Procoagulant State and Atherogenic Index in Rheumatoid Arthritis
NCT07357649Phase 4Not yet recruiting
- Sponsor
- Tanta University
- Start
- Jan 2026
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of baricitinib in rheumatoid arthritis (RA), sponsored by Tanta University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07357649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357649.